The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China | |
Xing, Puyuan; Zhu, Yixiang; Shan, Ling; Chen, Sipeng; Hao, Xuezhi; Li, Junling | |
2017 | |
卷号 | 8期号:50页码:87442-87454 |
关键词 | advanced non-small cell lung cancer (NSCLC) multiple treatments taxane nanoparticle albumin bound paclitaxel (Nab-PTX) secreted protein acidic and rich in cysteine (SPARC) |
ISSN号 | 1949-2553 |
DOI | 10.18632/oncotarget.21103 |
URL标识 | 查看原文 |
收录类别 | SCIE ; PUBMED |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/6363613 |
专题 | 中国医学科学院 北京协和医学院 |
推荐引用方式 GB/T 7714 | Xing, Puyuan,Zhu, Yixiang,Shan, Ling,et al. The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China[J],2017,8(50):87442-87454. |
APA | Xing, Puyuan,Zhu, Yixiang,Shan, Ling,Chen, Sipeng,Hao, Xuezhi,&Li, Junling.(2017).The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China.,8(50),87442-87454. |
MLA | Xing, Puyuan,et al."The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China".8.50(2017):87442-87454. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论